 Home > Biochemistry News > Biotechnology News > Eli Lilly and ProQR reach $1.3 billion collaboration on RNA editing therapy

Eli Lilly and ProQR reach $1.3 billion collaboration on RNA editing therapy

 Last Update: 2021-09-20
 Source: Internet
 Author: User

Tags

dopa used treat

single 25

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

Author: Shi Bei

On September 8, ProQR Therapeutics announced that it has reached a global licensing and research collaboration with Eli Lilly to discover, develop and commercialize potential new drugs for the treatment of genetic diseases of the liver and nervous system

The two companies will cooperate to develop up to 5 target drugs

ProQR's proprietary next-generation RNA editing Axiomer® platform technology can edit individual nucleotides in RNA in a highly targeted and specific manner

ProQR Therapeutics official website

The main area of ProQR's layout is hereditary retinal diseases, such as Leber congenital amaurosis, Usher syndrome and retinitis pigmentosa.

Sepofarsen (QR-110) is used to treat congenital amaurosis, which currently has no approved treatment

QR-421a is a potential first-in-class RNA therapy for USH2A exon 13 mutations.

The cooperation with Eli Lilly will expand ProQR's product layout from ophthalmology to liver and nervous system diseases, and improve the company's financial status

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.